Quantcast

Latest Takeda Pharmaceutical Company Limited Stories

2014-07-10 08:29:02

OSAKA, Japan and DURHAM, N.C., July 10, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference(®) 2014 (AAIC(®)), taking place in Copenhagen, Denmark from July 12-17, 2014. "Studies show that individuals with mild cognitive impairment--a slight, although noticeable and measurable...

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-06-16 08:27:34

Takeda and Lundbeck to Present Late-breaker at International College of Neuropsychopharmacology World Congress VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive...

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-04-08 00:22:26

DEERFIELD, Ill., April 8, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 the jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. The trial began...

2014-03-31 16:26:29

EMERYVILLE, Calif. and OSAKA, Japan, March 31, 2014 /PRNewswire/ -- Trianni, Inc. ("Trianni") and Takeda Pharmaceutical Company Limited ("Takeda") jointly announced today that they have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the...

2014-03-27 08:34:15

Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome WASHINGTON and OSAKA, Japan, March 27, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome)...

2014-02-20 12:27:47

Takeda will advance the CEOi's goal of building global momentum behind the G8's 2025 commitments WASHINGTON, Feb. 20, 2014 /PRNewswire-USNewswire/ -- The Global CEO Initiative (CEOi) on Alzheimer's Disease today announced that Takeda Pharmaceutical Company Limited ("Takeda") will join the CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and Dementia, building momentum behind the G8's commitment to stop the disease by...

2014-01-07 08:31:26

PUNE, India, January 7, 2014 /PRNewswire/ -- Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Company, announced today that it has received the first year milestone in its Research and Development Collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone underscores the success of the collaboration and also provides validation of Advinus' capabilities in innovative Drug Discovery and Takeda's confidence in these...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related